July 20, 2018

Monobind Inc. Anthony Shatola Quality Director 100 North Pointe Drive Lake Forest, CA 92630

Re: K181017 Trade/Device Name: Free Testosterone AccuBind ELISA Test System Regulation Number: 21 CFR 862.1680 Regulation Name: Testosterone test system Regulatory Class: Class I, reserved Product Code: CDZ Dated: June 18, 2018 Received: June 19, 2018

Dear Anthony Shatola:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR

Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice   
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn   
(http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

# Kellie B. Kelm -S

Courtney H. Lias, Ph.D.GPS Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

510(k) Number (if known) k181017

Device Name Free Testosterone AccuBind $^ \mathrm { \textregistered }$ ELISA Test System

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

# 510(k)Summary

1. Submittedby: MonobindInc. Address: 100 North Pointe Drive Lake Forest, CA 92630, USA Phone: 949-951-2665 Fax: 949-951-3539 Website: www.monobind.com CompanyContact: AnthonyShatola,QualityDirector Date: July 12, 2018   
2. ProductTradeName: FreeTestosterone AccuBind®ELISATest system FDASubmissionNumber: k181017 Classification Name: Radioimmunoassay,testosterone and dihydrotestosterone ProductCode: CDZ Classification: Class I, Reserved Regulation Number / Panel: 862.1680 / ClinicalChemistry   
3. Predicate Device: EiAsyFreeTestosterone EIA CompanyName: Diagnostic Biochem Canada,Inc. 510(k)Number: k030730

A. TestPrinciple:

Monobind Inc. Free Testosterone test system uses a competitive enzyme immunoassay. The essential reagents required for a solid phase enzyme immunoassay include immobilized antibody, enzyme-antigen conjugate and native antigen. Upon mixing immobilized antibody, enzyme-antigen conjugate and a serum containing the native antigen, a competition reaction results between the native antigen and the enzyme-antigen conjugate for a limited number of insolubilized binding sites. After equilibrium is attained, the antibody-bound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity in the antibody-bound fraction is inversely proportional to the native antigen concentration. By utilizing several different serum references of known antigen concentration, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained. The serum calibrators are prepared in human serum matrix. The enzyme-antigen conjugate is labelled with horseradish peroxidase (HRP) and the substrate reagent contains tetramethylbenzidine (TMB), a blue color is produced. The reaction is stopped with addition of an acid and a yellow color is developed. The plate is read in a microtiter plate reader at $4 5 0 \mathsf { n m }$ .

# B. KitDescription:

The kit consists of seven (7) vials of serum reference calibrators for Free Testosterone with two (2) controls (one low and one high); one (1) vial of Testosterone (Analog)-horseradish peroxidase (HRP) conjugate in a protein stabilizing matrix; one 96-well testosterone antibody-coated microplate; one (1) vial of concentrated wash solution; two (2) vials for tetramethylbenzidine (TMB) substrate solution preparation; and one (1) vial of stop reaction solution.

C. Indications for Use:

The Free Testosterone AccuBind $\textsuperscript { \textregistered }$ ELISA Test System is an Enzyme Immunoassay (EIA) for the quantitative measurement of free testosterone in human serum. Measurement of free testosterone is used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, impotence in males and in females; hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries and adrogenital syndromes.

Comparison withPredicate (EiAsyFreeTestosterone EIA):

Similarities and Differences

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>Monobind</td></tr><tr><td rowspan=1 colspan=1>IntendedUse</td><td rowspan=1 colspan=1>The direct quantitativedetermination of FreeTestosteronebyenzymeimmunoassayin human serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Utilizes a highly specific rabbitpolyclonal antibody at a lowbindingcapacity</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>DetectionMethod</td><td rowspan=1 colspan=1>Microplatecolorimetricreader</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>TestPrinciple</td><td rowspan=1 colspan=1>Competitive EnzymeImmunoassay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>HumanSerum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Key Reagents</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Six (6) vials containingtestosterone in human serumwith preservative</td><td rowspan=1 colspan=1>Seven (7) vials containingtestosterone in human serum withpreservative</td></tr><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>Two (2) vials containingtestosterone in human serum</td><td rowspan=1 colspan=1>Three (3) vials containingtestosterone in human serum</td></tr><tr><td rowspan=1 colspan=1>Calibrator/Control Matrix</td><td rowspan=1 colspan=1>HumanSerum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>HRPconjugate</td><td rowspan=1 colspan=1>Testosterone-HRP conjugatein buffer</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Wash BufferConcentrate</td><td rowspan=1 colspan=1>Concentrated (10x) buffer withpreservatives</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>TMBSubstrate</td><td rowspan=1 colspan=1>One vial containingtetramethylbenzidine andhydrogen peroxide in buffer</td><td rowspan=1 colspan=1>Two (2) vials: one containingtetramethylbenzidine,onecontaininghydrogenperoxide</td></tr><tr><td rowspan=1 colspan=1>Microplate</td><td rowspan=1 colspan=1>Antibody coated plate</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimentreatment</td><td rowspan=1 colspan=1>Direct system; no specimenpretreatmentnecessary</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring range</td><td rowspan=1 colspan=1>0.018-60 pg/ml</td><td rowspan=1 colspan=1>0.11-60pg/ml</td></tr><tr><td rowspan=1 colspan=1>Expected Range of values(pg/ml)</td><td rowspan=1 colspan=1>Males /20-39: 9.1-32.2Males / 40-59: 5.7-30.7Males /≥60: 5.9-27.0Females /20-39: 0.1-6.3Females / 40-59: 0.3-5.0Females/≥60: 0.5-3.9</td><td rowspan=1 colspan=1>Males /20-39: 9.2-34.6Males / 40-59: 6.1-30.3Males/≥60: 6.1-27.9Females / 20-39: 0.2-6.1Females / 40-59: 0.3-4.4Females/≥60: 0.5-3.4</td></tr></table>

# TestSummary

# 1. AnalyticalPerformance

a. Precision

This study was conducted during 20 days of testing. The human serum and control samples were tested in duplicate, two times per day for a total of 80 measurements per sample. Three (3) different reagent lots, three (3) serum pools, and three (3) controls were used for the study (low, medium, and high concentration). The results of a representative lot are shown below:

The results of the combined lot precision are shown below:   

<table><tr><td rowspan=2 colspan=1>Lot 1N=32</td><td rowspan=2 colspan=1>Mean (pg/ml)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>2.51</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>7.8%</td></tr><tr><td rowspan=1 colspan=1>Control2</td><td rowspan=1 colspan=1>10.98</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>8.7%</td></tr><tr><td rowspan=1 colspan=1>Control 3</td><td rowspan=1 colspan=1>22.72</td><td rowspan=1 colspan=1>0.83</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>2.18</td><td rowspan=1 colspan=1>9.6%</td></tr><tr><td rowspan=1 colspan=1>Serum 1</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>5.9%</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>12.4%</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>4.53</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>8.0%</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>53.62</td><td rowspan=1 colspan=1>4.24</td><td rowspan=1 colspan=1>7.9%</td><td rowspan=1 colspan=1>4.32</td><td rowspan=1 colspan=1>8.1%</td></tr></table>

<table><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>MeanValue(pg/ml)</td><td rowspan=1 colspan=2>Within-RunPrecision</td><td rowspan=1 colspan=2>Within-Kit Precision</td><td rowspan=1 colspan=2>TotalPrecision(n=80)</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>2.48</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>4.57</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>8.20</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>8.51</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>11.04</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>4.23</td><td rowspan=1 colspan=1>0.84</td><td rowspan=1 colspan=1>2.60</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>8.00</td></tr><tr><td rowspan=1 colspan=1>Control 3</td><td rowspan=1 colspan=1>23.24</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>4.31</td><td rowspan=1 colspan=1>1.80</td><td rowspan=1 colspan=1>7.73</td><td rowspan=1 colspan=1>1.83</td><td rowspan=1 colspan=1>7.95</td></tr><tr><td rowspan=1 colspan=1>Patient 1</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>4.88</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>9.14</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>9.43</td></tr><tr><td rowspan=1 colspan=1>Patient2</td><td rowspan=1 colspan=1>4.62</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>4.88</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>6.89</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>7.20</td></tr><tr><td rowspan=1 colspan=1>Patient 3</td><td rowspan=1 colspan=1>54.66</td><td rowspan=1 colspan=1>3.25</td><td rowspan=1 colspan=1>5.95</td><td rowspan=1 colspan=1>3.92</td><td rowspan=1 colspan=1>7.17</td><td rowspan=1 colspan=1>4.13</td><td rowspan=1 colspan=1>7.55</td></tr></table>

b. Linearity

Sample preparations of 11 concentrations were prepared $( 0 . 1 0 { - } 6 4 . 9 1 ~ \mathsf { p g / m L } )$ and assayed per CLSI EP06-A guidance, Evaluation of the Linearity of Quantitative Measurement Procedures. The linear regression obtained is as follows: $y = 1 . 0 1 4 9 x - 0 . 6 0 2 8$ , $\scriptstyle { \mathsf { R } } ^ { 2 } = 0 . 9 8 8 8$

c. Recovery

A study was performed to evaluate the recovery of the test system. Five serum samples containing different levels of endogenous testosterone were spiked with known concentrations of testosterone throughout the measuring range. The samples were measured in replicates of three and the average concentration was compared against the expected value. The recovery results are summarized below:

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Endogenous Concentration(pg/ml)</td><td rowspan=1 colspan=1>Average % Recovery</td></tr><tr><td rowspan=1 colspan=1>Patient Sample#1</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>100.2%</td></tr><tr><td rowspan=1 colspan=1>Patient Sample #2</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>102.4%</td></tr><tr><td rowspan=1 colspan=1>Patient Sample #3</td><td rowspan=1 colspan=1>5.65</td><td rowspan=1 colspan=1>98.7%</td></tr><tr><td rowspan=1 colspan=1>Patient Sample #4</td><td rowspan=1 colspan=1>0.91</td><td rowspan=1 colspan=1>104.0%</td></tr><tr><td rowspan=1 colspan=1>Patient Sample#5</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>105.2%</td></tr></table>

# d. ReagentStability/SampleStability

Real time stability studies are conducted to determine the reagent and kit shelf life (expiration date). Expiration date of the Monobind Free Testosterone AccuBind $\textsuperscript { \textregistered }$ ELISA Test System is determined by results of shelf studies and is based on the reagent that has the shorter assigned expirationdate.

1. The long term stability for kit reagents stored at $2 . 8 ~ ^ { \circ } \mathsf { C }$ is 2 years from the manufacturingdate.

2. Open vial, Free Testosterone Calibrator and controls, Free Testosterone Enzyme Reagentstabilitydetermination

SampleStability   

<table><tr><td rowspan=1 colspan=1>Condition</td><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>StorageTemperature</td></tr><tr><td rowspan=1 colspan=1>Open Kit Stability</td><td rowspan=1 colspan=1>61 days</td><td rowspan=1 colspan=1>2-8°</td></tr><tr><td rowspan=1 colspan=1>FreeTestosteroneCalibrators</td><td rowspan=1 colspan=1>61 days</td><td rowspan=1 colspan=1>2-8°</td></tr><tr><td rowspan=1 colspan=1>Free Testosterone Controls</td><td rowspan=1 colspan=1>61 days</td><td rowspan=1 colspan=1>2-8°</td></tr><tr><td rowspan=1 colspan=1>Free Testo Enzyme Reagent</td><td rowspan=1 colspan=1>61 days</td><td rowspan=1 colspan=1>2-8°</td></tr><tr><td rowspan=1 colspan=1>TMB Substrate(A&amp;B)</td><td rowspan=1 colspan=1>61 days</td><td rowspan=1 colspan=1>2-8°</td></tr><tr><td rowspan=1 colspan=1>AntibodyCoated Plate</td><td rowspan=1 colspan=1>61 days</td><td rowspan=1 colspan=1>2-8°</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Condition</td><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Storage Temperature</td></tr><tr><td rowspan=1 colspan=1>Serum Sample</td><td rowspan=1 colspan=1>61 days</td><td rowspan=1 colspan=1>2-8°</td></tr><tr><td rowspan=1 colspan=1>Frozen Serum Sample</td><td rowspan=1 colspan=1>31 days</td><td rowspan=1 colspan=1>-20 °</td></tr></table>

e. ExpectedReferenceValues

The reference range was established according to literature and verified utilizing 261 male and female serum samples. The reference range was calculated using CLSI C28-A3 as a guide. The following table indicates the summaryof the results.

<table><tr><td rowspan=1 colspan=1>Population</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>ReferenceRange (pg/ml)</td></tr><tr><td rowspan=1 colspan=1>Male / 20-39</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>9.2-34.6</td></tr><tr><td rowspan=1 colspan=1>Male / 40-59</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>6.1-30.3</td></tr><tr><td rowspan=1 colspan=1>Male /≥60</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>6.1-27.9</td></tr><tr><td rowspan=1 colspan=1>Female / 20-39</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>0.2-6.1</td></tr><tr><td rowspan=1 colspan=1>Female / 40-59</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0.3-4.4</td></tr><tr><td rowspan=1 colspan=1>Female/≥60</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>0.5-3.4</td></tr></table>

# f. DetectionLimits

The LOB (limit of the blank), the LOD (limit of detection) and the LOQ (limit of quantitation) were determined in accordance with CLSI EP 17-A guideline, Protocols for Determination of Limits of Detection).

<table><tr><td rowspan=1 colspan=1>Limit of the Blank (LoB)</td><td rowspan=1 colspan=1>Limit of Detection (LoD)</td><td rowspan=1 colspan=1>Limit of Quantitation (LoQ)</td></tr><tr><td rowspan=1 colspan=1>0.0295pg/ml</td><td rowspan=1 colspan=1>0.0519pg/ml</td><td rowspan=1 colspan=1>0.0519pg/ml</td></tr></table>

![](images/d0d270e24612dd6917e41004fcb12267dac1ae00ae31cc0dc38fb1bb965dee37.jpg)

# g. CrossReactivity

Cross reactivity was determined by testing those compounds most likely to interfere with the Monobind Free Testosterone ELISA Test System. The specificity of the assay was determined in accordance with CLSI EP07-A2. Cross-reactivity was determined using the following equation: observed value - unspiked value/ concentration of cross-reactant $\times 1 0 0 \%$ . Significant cross reactivity is defined as $>$ $10 \%$ difference. The results of the cross-reactivity study are as follows.

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Male SerumSpikedSamples</td><td colspan="2" rowspan="1">Blank SerumSpikedSamples</td></tr><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Conc.(ng/ml)</td><td colspan="1" rowspan="1">Conc(pg/ml)</td><td colspan="1" rowspan="1">CrossReactivity</td><td colspan="1" rowspan="1">Conc.(pg/ml)</td><td colspan="1" rowspan="1">CrossReactivity</td></tr><tr><td colspan="1" rowspan="1">Base Pool</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">7.408</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">11-Deoxycortisol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.269</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">11-KetoTestosterone</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">72.139</td><td colspan="1" rowspan="1">0.647%</td><td colspan="1" rowspan="1">51.855</td><td colspan="1" rowspan="1">0.519%</td></tr><tr><td colspan="1" rowspan="1">11β-Hydroxytestosterone</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">72.815</td><td colspan="1" rowspan="1">0.065%</td><td colspan="1" rowspan="1">54.000</td><td colspan="1" rowspan="1">0.054%</td></tr><tr><td colspan="1" rowspan="1">17α-ethynyl estradiol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.351</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">17α-Estradiol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.282</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.153</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">17β-Estradiol</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">7.363</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">17-Hydroxypregnenolone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.35</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">17-Hydroxprogesterone</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">7.969</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">1.012</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">3-EstriolGluc</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.825</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">3-EstriolSul</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">11.729</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">3β-Androstanediol</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">7.917</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">5α-Dihydrotestosterone</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">60.975</td><td colspan="1" rowspan="1">0.054%</td><td colspan="1" rowspan="1">42.382</td><td colspan="1" rowspan="1">0.042%</td></tr><tr><td colspan="1" rowspan="1">Aldosterone</td><td colspan="1" rowspan="1">8000</td><td colspan="1" rowspan="1">12.80</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">4.919</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">AmitriptyIHCI</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.301</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Androsterone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">8.061</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Andronstenedione</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">50.552</td><td colspan="1" rowspan="1">0.004%</td><td colspan="1" rowspan="1">19.248</td><td colspan="1" rowspan="1">0.002%</td></tr><tr><td colspan="1" rowspan="1">Clomiphene Citrate</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.263</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Corsticosterone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">10.099</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.777</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Corstisone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">9.90</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.478</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Cortisol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.316</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.298</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Cyproteroneacetate</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">10.70</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">D-5-Androstene-3β,17β-diol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.782</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Danazol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">12.30</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">DHEA</td><td colspan="1" rowspan="1">100000</td><td colspan="1" rowspan="1">7.311</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">7.457</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">DHEA-S</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.45</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.238</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Desogestrel</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">7.436</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Dexamethasone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.381</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Epistestosterone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">21.612</td><td colspan="1" rowspan="1">0.001%</td><td colspan="1" rowspan="1">8.215</td><td colspan="1" rowspan="1">0.001%</td></tr><tr><td colspan="1" rowspan="1">Estriol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.368</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.122</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Estrone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.679</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.036</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Ethisterone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">8.597</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.003</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Conc.(ng/ml)</td><td colspan="1" rowspan="1">Conc(pg/ml)</td><td colspan="1" rowspan="1">CrossReactivity</td><td colspan="1" rowspan="1">Conc.(pg/ml)</td><td colspan="1" rowspan="1">CrossReactivity</td></tr><tr><td colspan="1" rowspan="1">Ethynodiol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">8.042</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.114</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Ethynodioldiacetate</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">7.563</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Flunisolide</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.456</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Fluoxymesterone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.450</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Lynestrol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.395</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Medoxyprogesteroneacetate</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.426</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Methyl Testosterone</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">7.163</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Mestranol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.338</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Norethindrone</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">7.541</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Norethinodroneacetate</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">7.428</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Norgestimate</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.478</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Norgestrel(Levonorgestrel)</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">7.463</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Norethynodrel</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">7.544</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Oxymetholone</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">7.401</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Prednisolone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.828</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Prednisone</td><td colspan="1" rowspan="1">800</td><td colspan="1" rowspan="1">10.442</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.966</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Progesterone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">11.025</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.248</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Salbutamol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">8.026</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">ND</td></tr><tr><td colspan="1" rowspan="1">Spironolactone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.310</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.112</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Stanozolol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">7.442</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.081</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Testosteroneenanthate</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">7.304</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.044</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Testosterone SO4</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">75.970</td><td colspan="1" rowspan="1">0.004%</td><td colspan="1" rowspan="1">28.182</td><td colspan="1" rowspan="1">0.003%</td></tr><tr><td colspan="1" rowspan="1">TestosteronePropionate</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">9.589</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">1.008</td><td colspan="1" rowspan="1">0.000%</td></tr><tr><td colspan="1" rowspan="1">Triamcinolone</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">7.544</td><td colspan="1" rowspan="1">0.000%</td><td colspan="1" rowspan="1">0.043</td><td colspan="1" rowspan="1">0.000%</td></tr></table>

An additional study was performed to evaluate the cross-reactivity effects of testosterone cypionate and testosterone undecanoate. Aliquots from pool of human serum with a free testosterone concentration of $3 8 . 4 ~ \mathsf { p g / m L }$ were spiked with $1 2 \ \mathrm { n g / m L }$ of testosterone cypionate and testosterone undecanoate. Cross-reactivity was determined using the following equation: observed value - unspiked value/ concentration of cross-reactant $\times 1 0 0 \%$ . Significant crossreactivity is defined as $>$ $10 \%$ difference. The results are summarized in the chart below:

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Conc.(ng/ml)</td><td rowspan=1 colspan=1>Conc(pg/ml)</td><td rowspan=1 colspan=1>CrossReactivity</td><td rowspan=1 colspan=1>Conc.(pg/ml)</td><td rowspan=1 colspan=1>CrossReactivity</td></tr><tr><td rowspan=1 colspan=1>TestosteroneCypionate</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>38.685</td><td rowspan=1 colspan=1>0.002%</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>0.000%</td></tr><tr><td rowspan=1 colspan=1>TestosteroneUndecanoate</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>38.262</td><td rowspan=1 colspan=1>-0.001%</td><td rowspan=1 colspan=1>0.015</td><td rowspan=1 colspan=1>-0.001%</td></tr></table>

# 3. MethodComparisonStudies

Tests were conducted for comparison between the Free Testosterone ELISA Test System and the predicate assay, EiAsy Free Testosterone EIA. The free testosterone concentrations of 137 samples ranging from $0 . { \dot { 1 } } 1 { - } 5 9 . 6 3 \ \mathsf { p g / m l }$ were compared. Comparison of the Monobind Free Testosterone AccuBind $\textsuperscript { \textregistered }$ ELISA Test System (new device) and the DBC EiAsy Free Testosterone EIA (predicate) show the following results:

<table><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Least Square RegressionAnalysis</td><td rowspan=1 colspan=1>CorrelationCoefficient</td></tr><tr><td rowspan=1 colspan=1>This Method (y)</td><td rowspan=1 colspan=1>y= 1.017x-0.244</td><td rowspan=1 colspan=1>0.997</td></tr><tr><td rowspan=1 colspan=1>Reference(x)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

4. Interferences

Using CLSI-A2 Interference Testing in Clinical Chemistry as a guide, potential interferents were tested utilizing charcoal-stripped human serum spiked with known concentrations of interferent.

The following results of $\%$ binding values even at higher than normal interferent levels indicate that there is no significant binding of the free testosterone-HRP conjugate.

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Highest concentration at which no significantinterferencewas observed</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>20 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Acetylcysteine</td><td rowspan=1 colspan=1>150 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Bilirubin Conjugated</td><td rowspan=1 colspan=1>15 mg/dl</td></tr><tr><td rowspan=1 colspan=1>BilirubinUnconjugated</td><td rowspan=1 colspan=1>20 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=1>100 ng/ml</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>6 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>503mg/dl</td></tr><tr><td rowspan=1 colspan=1>Creatine</td><td rowspan=1 colspan=1>30 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Dextran</td><td rowspan=1 colspan=1>5000 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Digoxin</td><td rowspan=1 colspan=1>6.1 ng/ml</td></tr><tr><td rowspan=1 colspan=1>Doxycycline</td><td rowspan=1 colspan=1>50 mg/L</td></tr><tr><td rowspan=1 colspan=1>Erythromycin</td><td rowspan=1 colspan=1>6 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Gentamicin</td><td rowspan=1 colspan=1>1 mg/dl</td></tr><tr><td rowspan=1 colspan=1>HAMA</td><td rowspan=1 colspan=1>440 ng/ml</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>3 U/ml</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500mg/dl</td></tr><tr><td rowspan=1 colspan=1>Human Serum Albumin</td><td rowspan=1 colspan=1>2.5 g/dl</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Immunoglobulin G</td><td rowspan=1 colspan=1>4 g/dl</td></tr><tr><td rowspan=1 colspan=1>Levodopa</td><td rowspan=1 colspan=1>20 mg/L</td></tr><tr><td rowspan=1 colspan=1>Lidocaine</td><td rowspan=1 colspan=1>1.2mg/dl</td></tr><tr><td rowspan=1 colspan=1>Lipemia(glycerides)</td><td rowspan=1 colspan=1>1000 mg/dl</td></tr></table>

The World Resource for Diagnostic Products   

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Highest concentration at which no significantinterferencewas observed</td></tr><tr><td rowspan=1 colspan=1>Methyldopa</td><td rowspan=1 colspan=1>20 mg/L</td></tr><tr><td rowspan=1 colspan=1>Nicotine</td><td rowspan=1 colspan=1>0.1 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Phenobarbital</td><td rowspan=1 colspan=1>15 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Protein:Total</td><td rowspan=1 colspan=1>10.5 g/dl</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>1110|U/ml</td></tr><tr><td rowspan=1 colspan=1>Salicylic Acid</td><td rowspan=1 colspan=1>60 mg/dl</td></tr><tr><td rowspan=1 colspan=1>SHBG</td><td rowspan=1 colspan=1>200 μg/ml</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>900mg/dl</td></tr><tr><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>500 mg/dl</td></tr></table>

# ConcludingStatement:

Taken together, the performance characteristics, comparison studies with a predicate device and acceptable statistical performance studies in this $5 1 0 ( \mathsf { k } )$ Class I, reserved submission demonstrates that the Monobind Free Testosterone AccuBind $\textsuperscript { \textregistered }$ ELISA Test System is safe and effective for its intended use and is substantially equivalent to the predicate device.